Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 206

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 206
---
 as well as contract termination costs.The Company’s 2024 restructuring charges, including the beginning and ending liability balances, are summarized below (in thousands): Employee Termination Benefits (1)Contract Termination CostsTotalBalance at December 31, 2023$— $— $—    Charges incurred3,220 1,709 4,929    Cash payments made / settled(1,985)(20)(2,005)Balance at December 31, 20241,235 1,689 2,924    Cash payments made / settled(1,225)(1,689)(2,914)Balance at September 30, 2025$10 $— $10 (1) During the year ended December 31, 2024, there was $3.6 million of employee termination benefits related to share-based compensation excluded from the table above as they are non-cash and recorded against additional paid-in capital.Acquisition-Related ExpensesThe Company recognized an acquisition-related credit of $0.3 million and costs of $2.2 million during the three and nine months ended September 30, 2025, respectively. These costs primarily related to third-party services and legal fees associated with the GQ Bio Acquisition. See Note 3, GQ Bio Therapeutics Acquisition, for more information.The Company recognized acquisition-related expenses of $0.3 million and $0.7 million during the three and nine months ended September 30, 2024, respectively. These costs primarily related to vacant and underutilized Flexion leases that were assumed from the Flexion Acquisition.Legal SettlementThe Company recognized $7.0 million of costs during the nine months ended September 30, 2025 related to the patent infringement suits against eVenus, Jiangsu Hengrui and Fresenius (each as defined below). For more information, see Note 16, Commitments and Contingencies.Legal Judgment The Company recognized other income of $23.1 million during both the three and nine months ended September 30, 2025 upon receipt of a cash payment associated with the U.S. District Court for the District of Nevada issuing judgment declaring that the Research Development Foundation was required to repay the Company the royalties on EXPAREL sales that the Company previously paid under protest. For more information, see Note 16, Commitments and Contingencies.

Pacira BioSciences, Inc.  |  Q3